Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2023) 142 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2023-186517

Published: 2023

Journal Articles

Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies

Alexander Roeth, Rong FU, Guangsheng He, Hazza A Alzahrani, Sheng-Chieh Chou, Yosr Hicheri, Maciej Kazmierczak, Viviane Lacorte Recova, Michihiro Uchiyama, ANA Maria Vladareanu, Leigh Beveridge, Simon Buatois, Muriel Buri, Dayu Shi, Nadiesh Balachandran, Sasha Srekovic, Phillip Scheinberg

Blood (2023) 142 (Supplement 1): 575.

https://doi.org/10.1182/blood-2023-177618

Published: 2023

Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Blood (2023) 142 (Supplement 1): 202.

https://doi.org/10.1182/blood-2023-174289

Published: 2023

Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Blood (2022) 140 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2022-171538

Published: 2022

Journal Articles

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Blood (2021) 138 (Supplement 1): 1420.

https://doi.org/10.1182/blood-2021-150025

Published: 2021

Journal Articles

TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)

Vladimir I. Vorobyev, Dok Hyun Yoon, Maciej Kaźmierczak, Sebastian Grosicki, Corrado Tarella, Angelo Genua, Jin Seok Kim, Debra Litwak, David Cohan, Ian W. Flinn, Pier Luigi Zinzani, Leo I. Gordon

Blood (2021) 138 (Supplement 1): 3545.

https://doi.org/10.1182/blood-2021-147564

Published: 2021

Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-137245

Published: 2020

Journal Articles

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, MD, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, MD PhD, Jacek Trelinski, Nichola Cooper, MD MRCP, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, MD, Stephen Jolles

Blood (2019) 134 (Supplement_1): 897.

https://doi.org/10.1182/blood-2019-129839

Published: 2019

Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD

Blood (2019) 134 (Supplement_1): 2652.

https://doi.org/10.1182/blood-2019-125924

Published: 2019

Journal Articles

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Elżbieta Patkowska, Andrzej Szczepaniak, Marta Baranska, Maciej Kazmierczak, Monika Paluszewska, Wieslaw Jedrzejczak, Renata Guzicka Kazmierczak, Wanda Knopinska Posluszny, Olga Grzybowska-Izydorczyk, Agnieszka Pluta, Jaroslaw Piszcz, Izabela Deren-Wagemann, Ewa Lech Maranda, Krzysztof Warzocha, Joanna Gora Tybor

Blood (2017) 130 (Supplement 1): 1311.

https://doi.org/10.1182/blood.V130.Suppl_1.1311.1311

Published: 2017

Journal Articles

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Elzbieta Patkowska, MD, Joanna Gora Tybor, MDPhD, Ewa Lech Maranda, MDPhD, Maciej Kazmierczak, MDPhD, Marta Baranska, MD PhD, Andrzej Szczepaniak, MD, Monika Paluszewska, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Renata Guzicka Kazmierczak, MD PhD, Wanda Knopinska Posluszny, MD PhD, Olga Grzybowska Izydorczyk, MD PhD, Jaroslaw Piszcz, MD PhD, Izabela Deren Wagemann, MD PhD, Krzysztof Warzocha, MD PhD

Blood (2015) 126 (23): 1321.

https://doi.org/10.1182/blood.V126.23.1321.1321

Published: 2015

NARROW

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement — Case Control Study of the Polish Adult Leukemia Group (PALG)

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only